Frank Torti, MD — Chairperson of the Board of Directors

Dr. Torti has served as a member of our board since September 2018. Since January 2020, Dr. Torti served as the Vant Chair of Roivant Sciences, Inc. (RSI), where he previously worked as Vant Investment Chair. Prior to joining RSI, Dr. Torti served as a Partner of New Enterprise Associates (NEA), specializing in investments in healthcare. Before NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti presently serves as Chairperson of the board of directors of Immunovant, Inc., Arbutus Biopharma Corp. and several private biopharmaceutical companies. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.

Atul Pande, MD — Lead Independent Director

Dr. Pande has served as a member of the board since March 2015. He serves as Chief Medical Advisor of PureTech Health, President of Verity BioConsulting, a drug development consulting firm, and Chief Medical Officer of Tal Medical, a clinical-stage medical device company. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D, at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. Dr. Pande is also a non-executive board member of Autifony Therapeutics and Karuna Pharmaceuticals. Dr. Pande received a Bachelor of Medicine, Bachelor of Surgery (MBBS) degree from the University of Lucknow, India, and completed his research fellowship training in psychiatry at the University of Michigan Medical School and postgraduate specialty training and psychiatry residency program at Western University.

Eric Venker, MD, PharmD

Eric Venker serves as Chief Operating Officer of Roivant Sciences. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility, including Chief of Staff to the CEO. Prior to joining Roivant, Dr. Venker was a physician at New York Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. While there, Eric served as the Chair of the Housestaff Quality Council and led operational initiatives to improve efficiencies across a large hospital system with $5 billion in annual revenue. Earlier in his career, Eric was a Clinical Pharmacist at Yale-New Haven Hospital. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.

Pavan Cheruvu, MD

Pavan Cheruvu, MD was named Axovant’s Chief Executive Officer in February 2018 and was appointed a member of the board in September 2018. Prior to joining Axovant, Dr. Cheruvu held roles of increasing responsibility at Roivant Sciences and was appointed to Roivant’s executive leadership team in 2017. He supported Axovant in numerous capacities throughout his time at Roivant. A board-certified physician, Dr. Cheruvu completed his residency in internal medicine at Johns Hopkins Hospital and continued his training in a clinical fellowship in cardiovascular medicine at the University of California, San Francisco. Prior to his medical training, Dr. Cheruvu was a management consultant at McKinsey & Company, where he focused on biopharmaceutical strategy. Dr. Cheruvu earned his B.S.E. in biomedical engineering, B.S.E. in electrical engineering, and A.B. in chemistry summa cum laude from Duke University, obtained his M.Sc. in computer science as a Rhodes Scholar at Oxford University, and obtained his M.D. from Harvard Medical School.

Berndt Modig

Mr. Modig has served as a member of the board since March 2015. He also serves as Chief Executive Officer of Pharvaris B.V. Previously, he served as Chief Financial Officer of Prosensa Holding N.V., a pharmaceutical company, from March 2010 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. From October 2003 to November 2008, Mr. Modig was Chief Financial Officer at Jerini AG where he directed private financing rounds, the company’s initial public offering in 2005, and its acquisition by Shire plc in 2008. Before that, Mr. Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products Inc. from 1999 to 2001. In previous positions, Mr. Modig was a Partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr. Modig currently serves on the supervisory board of Kiadis Pharma N.V. and was a director of Mobile Loyalty plc from 2012 to 2013. He is also a member of the Supervisory Board and audit committee chair of Centogene N.V. Mr. Modig received a bachelor’s degree in business administration, economics, and German from the University of Lund, Sweden, and an M.B.A. from INSEAD, Fontainebleau, France.

Senthil Sundaram

Mr. Sundaram has served as a member of our board since June 2019. He was most recently the Chief Financial Officer at Nightstar Therapeutics, until its acquisition by Biogen in June 2019. While at Nightstar, he was responsible for corporate finance and operations, business development, and strategy. He helped lead the execution of multiple equity offerings, as well as licensing and M&A transactions. Prior to joining Nightstar, Mr. Sundaram was the Vice President and Head of Business and Corporate Development at Intercept Pharmaceuticals, Inc. Previously, Mr. Sundaram spent 13 years in the healthcare investment banking groups at Lehman Brothers/Barclays, Citigroup and Lazard. Mr. Sundaram holds a B.S. in Computer Engineering and a B.A. in Economics from Brown University.

Kristiina Vuori, MD, PhD

Dr. Vuori has served as member of our board since October 2020. Since January 2010, Dr. Vuori has served as President and member of the Board of Directors of Sanford Burnham Prebys Medical Discovery Institute (SBP), one of the largest non-profit biomedical research centers in the U.S. with a focus on cancer, neurodegeneration, inflammatory and infectious diseases, heart disease and rare children’s disorders. Since January 1995, Dr. Vuori has also served as a Professor at SBP’s National Cancer Institute-designated Cancer Center. Previously, she served as SBP’s EVP for Scientific Affairs in 2008-2010, as Director of the Cancer Center in 2005-2013, and as Deputy Director of the Cancer Center in 2003-2005. Dr. Vuori currently serves or has served on the Board of Directors for American Association for Cancer Research, California Institute for Regenerative Medicine, California Breast Cancer Research Program, Sanford Consortium for Regenerative Medicine, UCSD Sanford Stem Cell Clinical Center, and Bionano Genomics, Inc. She was director of WebMD, Inc. until it was sold to KKR in 2017. Dr. Vuori holds M.D. and Ph.D. degrees from University of Oulu, Finland.

 
 

AXOVANT GENE THERAPIES

Eleven Times Square, 33rd Floor
New York, NY 10036
United States

+1-833-AXOVANT (1-833-296-8268)

  • Axovant Gene Therapies LinkedIn
  • Axovant Gene Therapies Twitter
  • Axovant Gene Therapies Facebook

AXOVANT SCIENCES GMBH

Viaduktstrasse 8
4051 Basel
Switzerland